Differential pre- and postsynaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 283, Issue 5 52-5, 2002, Pages

  Liang, Chang Seng ^a   Himura, Yoshihiro ^a   Kashiki, Michihiro ^a   Stevens, Suzanne Y ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; Neuronal norepinephrine uptake; Neuropeptide Y; Tyrosine hydroxylase

Indexed keywords

BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYANOIODOPINDOLOL; DESIPRAMINE; DOBUTAMINE; GLYOXYLIC ACID; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; IMMUNOCYTOCHEMISTRY; INOTROPISM; NERVE ENDING; NERVE INJURY; NONHUMAN; NORADRENALIN UPTAKE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RECEPTOR DENSITY; SYMPATHETIC NERVE;

EID: 0036839543     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01131.2001     Document Type: Article

References (56)

1. Albino Teixeira A, Azevedo I, Branco D, Rodrigues-Pereira E, and Osswald W. Sympathetic denervation caused by long-term noradrenaline infusions: Prevention by desipramine and superoxide dismutase. Br J Pharmacol 97: 95-102, 1989.
2. Anzai T, Yoshikawa T, Baba A, Nishimura H, Shiraki H, Nagami K, Suzuki M, Wainai Y, and Ogawa S. Myocardial sympathetic denervation prevents chamber-specific alteration of β-adrenergic transmembrane signaling in rabbits with heart failure. J Am Coll Cardiol 28: 1314-1322, 1996.
3. Azevedo ER, Newton GE, Floras JS, and Parker JD. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 101: 2053-2059, 2000.
4. Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kubler W, and Haass M. The neuronal norepinephrine transporter in experimental heart failure: Evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 33: 461-472, 2001.
5. Barger AC, Roe BB, and Richardson GS. Relation of valvular lesions and of exercise to auricular pressure, work tolerance and to development of chronic congestive failure in dogs. Am J Physiol 169: 384-399, 1952.
6. Bellinger DL, Felten SY, Collier TJ, and Felten DL. Noradrenergic sympathetic innervation of the spleen: IV. Morphometric analysis in adult and aged F344 rats. J Neurosci Res 18: 55-63, 126-129, 1987.
7. Bo̊hm M, La Rosee K, Schwinger RH, and Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25: 146-153, 1995.
8. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, and Ginsburg R. β-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89: 803-815, 1992.
9. Chidsey CA and Braunwald E. Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 18: 685-700, 1966.
10. Chidsey CA, Braunwald E, Morrow AG, and Mason DT. Myocardial norepinephrine concentration in man: Effects of reserpine and of congestive heart failure. N Engl J Med 269: 653-658, 1963.
11. Choi JY, Lee KH, Hong KP, Kim BT, Seo JD, Lee WR, and Lee SH. Iodine-123 MIGB imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 8: 4-9, 2001.
12. Cohen MD, Finberg J, Dibner-Dunlap M, Yuih SN, and Thames MD. Effects of desipramine hydrochloride on peripheral sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 258: R876-R882, 1990.
13. Davidson DM, Covell JW, Malloch CI, and Ross J Jr. Factors influencing indices of left ventricle contractility in the conscious dog. Cardiovasc Res 8: 299-312, 1974.
14. De la Torre JC. Standardization of the sucrose-potassium phosphate-glyoxylic acid histofluorescence method for tissue monoamines. Neurosci Lett 17: 339-340, 1980.
15. Delehanty JM, Himura Y, Elam H, Hood WB Jr, and Liang CS. β-adrenoceptor down-regulation in pacing-induced heart failure is associated with an increased interstitial norepinephrine content. Am J Physiol Heart Circ Physiol 266: H930-H935, 1994.
16. Dequattro V, Nagatsu T, Mendez A, and Verska J. Determinants of cardiac noradrenaline depletion in human congestive failure. Cardiovasc Res 7: 344-350, 1973.
17. Dong E, Yatani A, Mohan A, and Liang CS. Myocardial β-adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. Eur J Pharmacol 384: 17-24, 1999.
18. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, and Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93: 1667-1676, 1996.
19. Fan THM, Liang C-S, Kawashima S, and Banerjee SP. Alterations in cardiac β-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol 140: 123-132, 1987.
20. 2-adrenoceptors and neuropeptide Y1 receptors in rats with heart failure. Acta Physiol Scand 166: 285-291, 1999.
21. Franz RP, Elam HM, Youngman MR, Imai N, Shubert M, Bhayana JN, Mentzer RM Jr, and Liang CS. β-adrenergic receptor density correlates with norepinephrine uptake activity in the failing human heart (Abstract). J Am Coll Cardiol 17: 176A, 1991.
22. Fried G, Terenius L, Hökfelt T, and Goldstein M. Evidence for differential localization of noradrenaline and neuropeptide Y in neuronal storage vesicles isolated from rat vas deferens. J Neurosci 5: 450-458, 1985.
23. Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, and Eto T. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of β-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 24: 523-529, 1997.
24. Higgins CB, Pavelec R, and Vatner SF. Modified technique for production of experimental right-sided congestive heart failure. Cardiovasc Res 7: 870-874, 1973.
25. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, and Liang CS. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88: 1299-1309, 1993.
26. Kawai H, Mohan A, Hagen J, Dong E, Armstrong J, Stevens SY, and Liang CS. Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 278: H1708-H1716, 2000.
27. Kelly DT, Spotnitz HM, Beiser GD, Pierce JE, and Epstein SE. Effects of chronic right ventricular volume and pressure loading on left ventricular performance. Circulation 44: 403-412, 1971.
28. Kuhn DM, Arthur RE, Thomas DM, and Elferink LA. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: Possible relevance to Parkinson's disease. J Neurochem 73: 1309-1317, 1999.
29. Lahti RA and Maickel RP. The tricyclic antidepressants inhibition of norepinephrine uptake as related to potentiation of norepinephrine and clinical efficacy. Biochem Pharmacol 20: 482-486, 1971.
30. Levy MN and Blattberg B. The influence of cocaine and desipramine on the cardiac responses to exogenous and endogenous norepinephrine. Eur J Pharmacol 48: 37-49, 1978.
31. Liang CS, Fan THM, Sullebarger JT, and Sakamoto S. Decreased adrenergic neuronal uptake activity in experimental right heart failure: A chamber-specific contributor to beta-adrenoceptor down-regulation. J Clin Invest 84: 1267-1275, 1989.
32. Liang CS, Frantz RP, Suematsu M, Sakamoto S, Sullebarger JT, Fan THM, and Guthinger L. Chronic β-adrenoceptor blockade prevents the development of β-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs. Circulation 84: 254-266, 1991.
33. Liang CS, Rounds NK, Dong E, Stevens SY, Shite J, and Qin F. Alterations by norepinephrine of cardiac sympathetic nerve terminal function and myocardial β-adrenoceptor sensitivity in the ferret: Normalization by antioxidants. Circulation 102: 96-103, 2000.
34. Linderson Y, Baez S, and Segura-Aguilar J. The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclic norepinephrine ortho-quinone by DT-diaphorase. Biochim Biophys Acta 1200: 197-204, 1994.
35. 123I-metaiodobenzylguanidine uptake. J Nucl Med 42: 49-54, 2001.
36. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
37. Lundberg JM, Fried G, Pernow J, and Theodorsson-Norheim E. Co-release of neuropeptide Y and catecholamines upon adrenal activation in the cat. Acta Physiol Scand 126: 231-238, 1986.
38. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, and Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88: 136-145, 1993.
39. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, Loisance D, Castaigne A, and Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40: 917-923, 1999.
40. 123I-MIBG in the failing human heart. J Nucl Med 40: 224-231, 1999.
41. Nagatsu T, Levitt M, and Udenfriend S. Tyrosine hydroxylase, the initial step in norepinephrine biosynthesis. J Biol Chem 239: 2910-2917, 1964.
42. Nakamura I, Yoshikawa T, Anzai T, Baba A, Iwata M, Wainai Y, Suzuki M, and Ogawa S. Presynaptic modulation of the norepinephrine-induced beta-adrenergic receptor desensitization phenomenon in vivo. J Card Fail 6: 350-358, 2000.
43. 123I-metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: A prospective study. Heart 86: 656-660, 2001.
44. Peuler JD and Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci 21: 625-636, 1977.
45. Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Goldenberg IF, Reynolds S, and Cohn JN. Heterogenous myocardial catecholamine concentrations in patients with congestive heart failure. Am J Cardiol 60: 316-321, 1987.
46. Pool PE, Covell JW, Levitt M, Gibb J, and Braunwald E. Reduction of cardiac tyrosine hydroxylase activity in experimental congestive heart failure. Its role in the depletion of cardiac norepinephrine stores. Circ Res 20: 349-353, 1967.
47. Rose CP, Burgess JH, and Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest 76: 1740-1747, 1985.
48. Rutenberg HL and Spann JF Jr. Alterations of cardiac sympathetic neurotransmitter activity in congestive heart failure. Am J Cardiol 32: 472-480, 1973.
49. Sassa H. Mechanism of myocardial catecholamine depletion in cardiac hypertrophy and failure in rabbits. Jpn Circ J 35: 391- 403, 1971.
50. 3H]norepinephrine uptake in peripheral organs of some mammalian species by ouabain. Eur J Pharmacol 41: 417-429, 1977.
51. Shite J, Qin F, Mao W, Kawai H, Stevens SY, and Liang CS. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 38: 1734-1740, 2001.
52. Somsen GA, van der Wall EE, van Vlies B, Borm JJ, and van Royen EA. Neuronal dysfunction in heart failure assessed by cardiac 123-iodine metaiodobenzylguanidine scintigraphy. Int J Card Imaging 12: 305-310, 1996.
53. Spann JF Jr, Buccino RA, Sonnenblick EH, and Braunwald E. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res 21: 341-354, 1967.
54. Thoenen H and Tranzer JP. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn Schmiedebergs Arch Pharmacol 261: 271-288, 1968.
55. Watanabe K, Takahashi T, Nakazawa M, Wahed MII, Fuse K, Tanabe N, Kodama M, Aizawa Y, Ashino H, and Tazawa S. Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. J Nucl Med 43: 531-535, 2002.
56. Yoshikawa T, Handa S, Suzuki M, and Nagami IL Abnormalities in sympathoneuronal regulation are localized to failing myocardium in rabbit heart. J Am Coll Cardiol 24: 210-215, 1994.